Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant tumours after renal transplantation

D Fahlenkamp1, P Reinke, S Kirchner

  • 1Department of Urology, Charité Hospital, Medical School, Humboldt University Berlin.

Scandinavian Journal of Urology and Nephrology
|October 1, 1996
PubMed
Summary

Malignant tumors developed in 37 of 1243 renal transplant recipients. Tumor patients received fewer blood transfusions and experienced fewer rejection crises than controls, suggesting a link between transplantation factors and cancer risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgery for Renal Hyperparathyroidism in the Era of Cinacalcet: A Single-Center Experience.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2020
Same author

[Modern nephrolithiasis in the complex setting of metaphylaxis : Latest epidemiological data and a nationwide survey in private practices].

Der Urologe. Ausg. A·2019
Same author

The effect of induction therapy on established CMV specific T cell immunity in living donor kidney transplantation.

Physiological research·2018
Same author

Estimated Nephron Number of the Donor Kidney: Impact on Allograft Kidney Outcomes.

Transplantation proceedings·2017
Same author

Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Clinical Development of Cell Therapies: Setting the Stage for Academic Success.

Clinical pharmacology and therapeutics·2016

Area of Science:

  • Nephrology
  • Oncology
  • Immunology

Background:

  • Renal transplantation is a life-saving procedure.
  • Post-transplant malignancy is a known complication.
  • Understanding risk factors for cancer after transplantation is crucial.

Purpose of the Study:

  • To investigate the incidence and types of malignant tumors after renal transplantation.
  • To identify potential risk factors, including blood transfusions and rejection episodes, associated with post-transplant cancer.

Main Methods:

  • Retrospective analysis of 1243 renal transplant recipients.
  • Identification of 37 patients who developed 39 malignant tumors.
  • Comparison of pre-transplant blood transfusion history and rejection crisis rates between tumor patients and a control group.

Related Experiment Videos

Main Results:

  • 39 malignant tumors were detected in 37 patients, with an average latency of 72 months.
  • Malignant lymphomas (8), dermatomas (7), and visceral tumors (24) were observed.
  • Tumor patients received fewer pre-transplant blood transfusions compared to a tumor-free control group.
  • Tumor patients experienced significantly fewer rejection crises than the control group.

Conclusions:

  • Malignancy is a significant concern in long-term renal transplant survivors.
  • Reduced exposure to blood transfusions and fewer rejection episodes may be associated with a lower risk of developing cancer post-renal transplantation.
  • Further research is warranted to elucidate the complex interplay between immunosuppression, rejection, and oncogenesis in transplant recipients.